Trial
NCT02128269
Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
Antiphospholipid (aPL)-Positive
Intervention
Study Drug- ALXN1007
Why stopped
Screening discontinued early due to slow patient enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-07-13